Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F15%3A10295073" target="_blank" >RIV/00216208:11140/15:10295073 - isvavai.cz</a>
Nalezeny alternativní kódy
RIV/00669806:_____/15:10295073
Výsledek na webu
<a href="http://onlinelibrary.wiley.com/doi/10.1111/tid.12383/full" target="_blank" >http://onlinelibrary.wiley.com/doi/10.1111/tid.12383/full</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1111/tid.12383" target="_blank" >10.1111/tid.12383</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective
Popis výsledku v původním jazyce
INTRODUCTION: Valganciclovir (vGCV) and valacyclovir (vACV) are used in cytomegalovirus (CMV) prophylaxis in renal transplant recipients. The aim of this study was to compare the economic impact of both regimens during 1-year follow-up. METHODS: A totalof 117 renal transplant recipients at risk for CMV were randomized to 3-month prophylaxis either with vGCV (900 mg/day, n = 60) or vACV (8 g/day, n = 57) and their data used in a pharmacoeconomic analysis. The pharmacoeconomic evaluation involved all direct CMV-related expenses in the first year after transplantation. Sensitivity analysis was employed to examine the effects of various prices of antiviral drugs and diagnostic procedures on overall CMV-related costs. Simulation of the more expensive US healthcare perspective was performed, and a scenario involving costs of acute rejection (AR) was examined. RESULTS: Overall CMV-related costs were significantly lower in the vACV arm; median United States dollars (USD) 3473 (3108-3745) vs.
Název v anglickém jazyce
Valganciclovir versus valacyclovir prophylaxis for prevention of cytomegalovirus: an economic perspective
Popis výsledku anglicky
INTRODUCTION: Valganciclovir (vGCV) and valacyclovir (vACV) are used in cytomegalovirus (CMV) prophylaxis in renal transplant recipients. The aim of this study was to compare the economic impact of both regimens during 1-year follow-up. METHODS: A totalof 117 renal transplant recipients at risk for CMV were randomized to 3-month prophylaxis either with vGCV (900 mg/day, n = 60) or vACV (8 g/day, n = 57) and their data used in a pharmacoeconomic analysis. The pharmacoeconomic evaluation involved all direct CMV-related expenses in the first year after transplantation. Sensitivity analysis was employed to examine the effects of various prices of antiviral drugs and diagnostic procedures on overall CMV-related costs. Simulation of the more expensive US healthcare perspective was performed, and a scenario involving costs of acute rejection (AR) was examined. RESULTS: Overall CMV-related costs were significantly lower in the vACV arm; median United States dollars (USD) 3473 (3108-3745) vs.
Klasifikace
Druh
J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CEP obor
FE - Ostatní obory vnitřního lékařství
OECD FORD obor
—
Návaznosti výsledku
Projekt
<a href="/cs/project/ED2.1.00%2F03.0076" target="_blank" >ED2.1.00/03.0076: Biomedicínské centrum Lékařské fakulty v Plzni</a><br>
Návaznosti
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)<br>I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Ostatní
Rok uplatnění
2015
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Údaje specifické pro druh výsledku
Název periodika
Transplant Infectious Disease
ISSN
1398-2273
e-ISSN
—
Svazek periodika
17
Číslo periodika v rámci svazku
3
Stát vydavatele periodika
DK - Dánské království
Počet stran výsledku
8
Strana od-do
334-341
Kód UT WoS článku
000356082600002
EID výsledku v databázi Scopus
2-s2.0-84930758262